Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma

Leukemia Research

Volumn 29, Issue 10, 2005, Pages 1233-1234

  Kraut, Eric H ^a   Young, Donn ^a   Farag, Sherif ^a   James, Arthur G ^b   Solove, Richard J ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b Intensive Care Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TOPOTECAN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; LETTER; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; SALVAGE THERAPY; TOPOTECAN; TREATMENT FAILURE;

EID: 23844508120     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.03.003     Document Type: Letter

References (12)

1. A. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M.J. Thun Cancer statistics Cancer J Clin 53 2003 5 26
2. N. Munshi, G. Tricot, and B. Barlogie Plasma cell neoplasms V.T. DeVita S. Hellman S.A. Rosenberg Cancer: principles and practice of oncology 6th ed. 2001 Lippincott Williams and Wilkins Philadelphia 2465 2499
3. M. Attal, J.L. Harousseau, and A.M. Stoppa A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 1996 91 97
4. S.V. Rajkumar, M.A. Gertz, R.A. Kyle, and P.R. Greipp Current therapy for multiple myeloma Mayo Clin Proc 77 2002 818 822
5. M.A. Hussein, L. Wood, and E. His A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients Cancer 95 2002 2160 2168
6. R. Alexanian, D. Weber, A. Anagnostopoulos, K. Delasalle, M. Wang, and K. Rankin Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma Semin Hematol 40 Suppl. 4 2003 3 7
7. P.G. Richardson, B. Barlogie, and J. Berenson A phase II study of bortezomib in relapsed, refractory myeloma N Engl J Med 348 2003 2609 2617
8. E.H. Kraut, J.J. Crowley, and J.L. Wade Evaluation of topotecan in resistant and relapsing multiple myeloma: a southwest oncology group study J Clin Oncol 16 1998 589 592
9. D.E. Bergsagel, D.H. Cowan, and R. Hasselbach Plasma cell myeloma: response of melphalan resistant patients to high dose intermittent cyclophosphamide Can Med Assoc J 107 1972 851 855
10. J.R. Murren, S. Anderson, and J. Fedele Dose escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer J Clin Oncol 15 1997 148 157
11. R. Simon Optimal two-stage design for phase II clinical trials Con Clin Trials 10 1989 1 10
12. B.G.M. Durie, and S.E. Salmon A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 36 1975 842 854